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are reduced, and the percentage of patients requiring surgery
decreases. Inﬂiximab should be used on a maintenance schedule
rather than episodically (i.e.: treatment of ﬂares) in order to
optimize treatment outcomes.
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OBJECTIVES: It has been recommended that due to a lack of
evidence, screening for hereditary hemochromatosis should be
rejected and instead, further research is warranted. This study
builds on a published quantitative synthesis of evidence and
assesses the expected value of perfect information (EPVI) as an
upper bound of value for further research. Implications of
modelling results and EVPI for both Bayesian and Frequentist
decision makers with different cost-effectiveness thresholds are
discussed. METHODS: Expected value of information both for
the decision, for single and for groups of parameters are calcu-
lated. Population EVPI was based on an inﬁnite time horizon for
the target cohort of 30 years old Germans. RESULTS: A Fre-
quentist decision maker can be assumed to reject screening based
on a lack of high quality evidence of cost-effectiveness at thresh-
olds between 50,000 and 100,000 EUR/LYG. In contrary, for a
Bayesian with a cost-effectiveness threshold of 50,000 or beyond
100,000 EUR/LYG evidence may be sufﬁcient: The former will
probably reject, the latter pursue population screening. The
overall costs of uncertainty for the decision are comparatively
small: the total expected value of perfect information at a cost-
effectiveness threshold of 50,000 EUR/LYG was calcu-lated to be
approximately 1 million EUR. Uncertainty about compliance
had the highest expected value of partial perfect information of
approx. 200,000 EUR. CONCLUSION: Further research on
genetics in health care should include the issue of patient com-
pliance. Frequentist decision making incurs costs in terms of
expected health forgone. Yet the Frequentist decision is more
stable: Given the deterioration of cost-effectiveness ratios in past
economic studies, a Bayesian decision maker with a threshold of
EUR 50,000/LYG may have introduced screening years ago while
a Frequentist decision maker would always have rejected
it. Coverage with evidence development may bridge the gap
between both.
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OBJECTIVES: Certolizumab pegol, a PEGylated anti-TNFa
fragment, induced and maintained health-related quality of life
(HRQoL) at levels that are indicative of remission in patients
with active Crohn’s disease (CD) in the PRECiSE 2 trial
(Schreiber et al., 2005). HRQoL was assessed using the Inﬂam-
matory Bowel Disease Questionnaire (IBDQ), which evaluates
four domains: bowel symptoms (BS), systemic symptoms (SS),
emotional function (EF) and social function (SF). The SF-36 and
EQ-5D were administered and utility scores determined. A
strong relationship was documented recently between both
preference-based measures and the IBDQ scores in patients with
CD (Buxton et al., 2007). Using PRECiSE 2 data, this analysis
evaluated the correlations between changes in IBDQ scores and
changes in utility indexes derived from the EQ-5D and SF-6D in
patients with active CD. METHODS: EQ-5D and SF-6D utility
scores were derived using the established algorithms (Dolan
et al., 1995 and Brazier et al., 2002, respectively). The changes in
IBDQ domains and total score were paired to the changes in
utility scores between Weeks 0 and 26. Correlations between 405
(EQ-5D) and 375 (SF-6D) paired observations were calculated
using Spearman coefﬁcients. RESULTS: The strength of the asso-
ciation between changes in utility scores and IBDQ scores was
two to four times larger when using the EQ-5D (Spearman
coefﬁcients 0.48 [SF] to 0.58 [total score]) compared with
the SF-6D (Spearman coefﬁcients 0.13 [SF] to 0.23 [EF]). All
coefﬁcients were statistically signiﬁcant: p-values <0.0001 with
the EQ-5D and <0.0001 (EF) to 0.0151 (SF) with the SF-6D.
CONCLUSION: Changes in IBDQ scores were associated with
consistent changes in both EQ-5D and SF-6D utility scores in
patients with active CD. However, the magnitude of the correla-
tion coefﬁcients suggests that the EQ-5D is more sensitive to
HRQoL changes than the SF-6D in CD.
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OBJECTIVES: To identify the strength of the study participants’
preferences for the different treatments and outcomes of GORD
and to investigate whether these preferences differ between the
different arms of the REFLUX trial. METHODS: A qualitative
study and expert advice were used to identify four dimensions
related to the treatment and outcomes of care. These were:
frequency of troublesome symptoms, chance of serious compli-
cations, chance of undergoing surgery, and chance of needing life
long medication. The questionnaires were sent to participants in
the 4 arms of the REFLUX trial (randomised medical, ran-
domised surgical, prefer medical, prefer surgical). Data were
analysed using logistic regression techniques. RESULTS: The
most important dimension was serious complications, followed
by the chance of having surgery or receiving lifelong medication.
Suffering troublesome symptoms most days was least important.
There was no evidence that treatment group had any effect
on preferences for either ‘troublesome symptoms’ or ‘serious
complications’. However, preferences differed for ‘surgery’ and
‘lifelong medications’. CONCLUSION: The DCE aids the
interpretation of the clinical evidence by indicating the impor-
tance placed on type of treatment and a treatment’s ability to
resolve symptoms. The results of the analysis highlight the impor-
tance of quantifying the risk of serious complications and of
considering patient choice when decisions are made the types of
treatment to provide and the type of treatment to recommend.
GI DISORDERS—Patient Reported Outcomes
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OBJECTIVES: The short, self-administered Gastroesophageal
Reﬂux Disease (GERD) Symptom Frequency Questionnaire
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(GSFQ) is a speciﬁc Quality of Life (QoL) instrument which
measures the impact of GERD symptoms on QoL. This study
aims to adapt the GSFQ into Spanish (for Spain) culture and
check the questionnaire psychometric properties. METHODS:
An expert panel composed by a gastroenterologist, two method-
ologists, one expert in clinical research and one pharmacoecono-
mist supervised the adaptation process. The original instrument
was translated and back-translated by two independent transla-
tors. For psychometric measures, a small sample was used to
check the initial comprehension and factibility. A national rep-
resentative sample was selected, stratiﬁed by gender, age (<45,
45 years) and GERD severity (0-I, II, Savary-Miller score).
Content validity was ensured by the original instrument. Cron-
bach’s Alfa was used to assess reliability, and exploratory factor
analysis to assess dimensionality. The EuroQol questionnaire and
corresponding Visual analogue scales (VAS) were used for con-
current validity. RESULTS: A total of 3997 patients with pyrosis
symptoms were recruited by 490 clinicians. Mean age was 49.35
(14.35) years and 48.4% were women. No ceiling or ﬂoor effects
were detected in item responses. The reliability was good (0.864)
and only 1 dimension exhibited an eigenvalue (3.45) above 1,
explaining 58% of available variability. All items loaded on
this dimension. Correlation were moderate but signiﬁcant
(p < 0.001) with EuroQol (0.499) and VAS (-0.481). The
average score was 34.17 (19.685), in the 0–100 scale. Mean
scores were signiﬁcantly different between GERD diagnosed
severity levels (F4,33035 = 84.9, p < 0.005), but no differences were
found between Savary-Miller level IV and levels II-III. CON-
CLUSION: The Spanish version of the GSFQ has good psycho-
metric properties, behaves as a unidimensional scale, and is
capable to discriminate between patients with varying degrees of
GERD severity.
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OBJECTIVES: According to recently published guidelines,
treatments effects on patient’s health status should be measured
by validated disease-speciﬁc Patient Reported Outcomes con-
cepts. The aim of this study is to develop and validate a PRO
questionnaire based on a conceptual framework for Crohn’s
disease. METHODS: An item pool of 77 items was generated
through in focus groups and validated in a German sample
(n = 104). Other data included the SF-36 and IBDQ. RESULTS:
A principal component analysis revealed 7 independent factors:
impact, intimacy, abdominal pain, bowel movements, nausea,
extraintestinal problems and night sweat. The impact factor
was shown to comprise further three interpretable domains:
emotional, social, and physical. CONCLUSION: Symptoms
and consequences of Crohn’s disease need to be measured sepa-
rately, since their constituent items do not load on the same
factors. Further investigation could reduce the amount of items
of one concept or ﬁnd further items for relevant aspects such as
problems with intimacy.
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OBJECTIVES: To quantify the effects of chronic constipation on
health-related quality of life, work productivity, and activity
impairment. METHODS: Data are taken from the 2005 U.S.
National Health and Wellness Survey, an annual cross-sectional
study of the health care attitudes and behaviors of adults (age
18+). Chronic constipation sufferers are deﬁned as experiencing
chronic constipation in the past twelve months, and non-sufferers
have not experienced chronic constipation. Respondents who
experience inﬂammatory bowel disease or irritable bowel syn-
drome are excluded from the analysis. Quality of life is deﬁned
using the SF-8. The Work Productivity and Activity Impairment
(WPAI) scale is used to quantify productivity loss. Linear regres-
sion models are used to control for potential confounders includ-
ing demographics, number of physical comorbid conditions, and
experiencing psychiatric comorbid conditions. RESULTS: The
sample includes 1,288 (3%) chronic constipation sufferers and
35,676 (97%) non-sufferers. Chronic constipation sufferers
have signiﬁcantly worse mean physical (40.08 versus 48.79,
p < 0.001) and mental (42.13 versus 49.75, p < 0.001) quality of
life than non-sufferers. Controlling for potential confounders,
constipation sufferers have SF-8 physical summary scores that
are 3.550 (p < 0.001) points lower and SF-8 mental summary
scores that are 2.891 (p < 0.001) points lower than non-sufferers.
Among respondents employed full-time, chronic constipation
sufferers have signiﬁcantly greater productivity loss due to absen-
teeism (8.35 versus 3.10, p < 0.001), presenteeism (29.36 versus
13.36, p < 0.001), and overall (25.54 versus 12.18, p < 0.001).
Controlling for potential confounders, constipation sufferers
have greater absenteeism scores (3.102 points higher, p < 0.001),
presenteeism scores (7.782 points higher, p < 0.001), and overall
work productivity loss (6.017 points higher, p < 0.001) than
non-sufferers. Chronic constipation sufferers also experience
greater activity impairment (48.71 versus 21.75, p < 0.001) than
non-sufferers, and have activity impairment scores 11.708 higher
(p < 0.001) after controlling for potential confounders. CON-
CLUSION: Chronic constipation has signiﬁcant negative effects
on physical and mental quality of life, work productivity, and
activity impairment.
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OBJECTIVES: To obtain the multi-attribute utility function
(MAUF) for the Spanish version of the Short Form 6-D (SF-6D)
and to compare utilities values with those determined by the
British MAUF. To determine the weights of SF-36v1 items con-
forming the SF-6D instrument. METHODS: A whole-nation rep-
resentative sample of 2,549 subjects [48.9% men, 48.5 (14.01)
years] with mild to severe degree of Gastroesophageal Reﬂux
Disease was recruited by 500 clinicians selected at random and
used for this analysis. The Spanish versions of SF-6D and EQ-5D
questionnaires plus the corresponding visual analogue scale were
self-completed. Attribute weights were estimated using a cat-
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